NCT05698628 Distal Perfusion Timing, Early or Conservative, to Prevent Limb Ischemia During Peripheral VA-ECMO
| NCT ID | NCT05698628 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Min-Seok Kim |
| Condition | Extracorporeal Membrane Oxygenation Complication |
| Study Type | INTERVENTIONAL |
| Enrollment | 400 participants |
| Start Date | 2023-04-28 |
| Primary Completion | 2027-02-28 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 400 participants in total. It began in 2023-04-28 with a primary completion date of 2027-02-28.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Peripheral VA-ECMO is widely used in refractory cardiogenic shock patients as a salvage therapy. In most cases, the femoral artery and vein are used for the vascular approach. Large cannulas are usually used for proper oxygenation, which may cause peripheral limb ischemia. Distal perfusion catheterization (DPC) at the ipsilateral arterial cannula site is recommended to prevent distal limb ischemia. However, there is no consensus on the proper timing of DPC and additional invasive procedures may cause complications during VA-ECMO support. In this analysis, the investigators compare the clinical outcomes of distal limb ischemia complications between the conventional DPC group (DPC at the time of limb ischemia sign) and the preemptive DPC group (DPC at the time of VA-ECMO application).
Eligibility Criteria
Inclusion Criteria: * Age ≥19 years old * Refractory cardiogenic shock with peripheral VA-ECMO * Informed consent Exclusion Criteria: * Unwilling or unable to obtain informed consent from the participant or substitute decision-maker * Patients who are currently pregnant, postpartum period within 30 days or are breast-feeding * VA-ECMO application for causes other than cardiogenic shock * Severe coagulopathy * Irreversible limb ischemia requiring interventional procedures or surgery at the time of VA-ECMO (previously diagnosed ASO(atherosclerosis obliterans) patients)
Contact & Investigator
Min-Seok Kim
STUDY CHAIR
Asan Medical Center
Frequently Asked Questions
Who can join the NCT05698628 clinical trial?
This trial is open to participants of all sexes, aged 19 Years or older, studying Extracorporeal Membrane Oxygenation Complication. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05698628 currently recruiting?
Yes, NCT05698628 is actively recruiting participants. Contact the research team at msk@amc.seoul.kr for enrollment information.
Where is the NCT05698628 trial being conducted?
This trial is being conducted at Seoul, South Korea.
Who is sponsoring the NCT05698628 clinical trial?
NCT05698628 is sponsored by Min-Seok Kim. The principal investigator is Min-Seok Kim at Asan Medical Center. The trial plans to enroll 400 participants.